Last Updated: September 7, 2026

Investigational Drug Information for BLD-0409


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for BLD-0409?

BLD-0409 is an investigational drug.

There have been 5 clinical trials for BLD-0409. The most recent clinical trial was a Phase 1 trial, which was initiated on May 31st 2022.

The most common disease conditions in clinical trials are Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, and Fibrosis. The leading clinical trial sponsors are Blade Therapeutics and [disabled in preview].

There are eighteen US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for BLD-0409
TitleSponsorPhase
RESPIRARE Phase 2 Study of Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)Blade TherapeuticsPhase 2
Dedicated Drug-Drug Interaction (DDI) Study in Healthy VolunteersBlade TherapeuticsPhase 1
Healthy Volunteer Study Comparing Tablet and Oral Solution FormulationsBlade TherapeuticsPhase 1

See all BLD-0409 clinical trials

Clinical Trial Summary for BLD-0409

Top disease conditions for BLD-0409
Top clinical trial sponsors for BLD-0409

See all BLD-0409 clinical trials

US Patents for BLD-0409

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BLD-0409 ⤷  Start Trial Autotaxin inhibitors and uses thereof SABRE THERAPEUTICS LLC (South San Francisco, CA) ⤷  Start Trial
BLD-0409 ⤷  Start Trial Autotaxin inhibitor compounds Df 2024 Ip Acquisition LLC , Sabre Therapeutics LLC ⤷  Start Trial
BLD-0409 ⤷  Start Trial Autotaxin inhibitor compounds Df 2024 Ip Acquisition LLC , Sabre Therapeutics LLC ⤷  Start Trial
BLD-0409 ⤷  Start Trial Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof Gilead Sciences Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BLD-0409

Drugname Country Document Number Estimated Expiration Related US Patent
BLD-0409 Australia AU2016268250 2035-05-27 ⤷  Start Trial
BLD-0409 Australia AU2020239656 2035-05-27 ⤷  Start Trial
BLD-0409 Australia AU2022228098 2035-05-27 ⤷  Start Trial
BLD-0409 Brazil BR112017025420 2035-05-27 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.